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Autologous stem cell transplantation (ASCT) is considered the standard of care in younger patients diagnosed with 
multiple myeloma (MM). However, despite an increase in the number of sustained responses, MM remains an incu-
rable disease. Allogeneic stem cell transplantation (alloSCT) may have a curative potential resulting from induction 
of graft-versus-myeloma effect, but several factors limit its implementation in routine clinical practice. Myeloablative 
conditioning is associated with high (> 30%) treatment-related mortality (TRM), primarily due to graft-versus-host 
disease and infections, while the use of reduced-intensity conditioning increases the risk of relapse and disease 
progression, and also results in an unacceptably high TRM (21–23%). Auto/allotransplantation is not superior to 
tandem ASCT in terms of progression-free survival and overall survival, even in high-risk MM patients. The majority 
of younger patients may achieve sustained remissions after novel agents and ASCT, and nowadays alloSCT should 
be considered mainly in the context of clinical trials.
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Introduction
Autologous stem cell transplantation (ASCT) is consi-
dered the standard of care in younger patients diagnosed 
with multiple myeloma (MM) [1, 2]. Despite a significant 
improvement in treatment outcomes, resulting primarily 
from the use of novel agents in induction, consolidation 
and maintenance therapy, MM still remains an incurable 
disease [3]. Although the term “operational cure”, referring 
to progression-free survival (PFS) longer than 10 years, was 
established [4–6], still there is no medication potent enough 
to kill all neoplastic cells. Theoretically, allogeneic stem cell 
transplantation (alloSCT) could be a curative option, due 
to immunologic effect of the graft, the so-called graft-ver-
sus-myeloma (GVM) effect, exerted by immunocompetent 
donor lymphocytes [7, 8]. Unfortunately, it is theoretical 
only. The role of alloSCT in MM treatment has been widely 
discussed in the recent decades. Early studies, conducted in 
Europe in 1990s, revealed that full myeloablative allogeneic 
transplantation (the so-called “full allo”) is associated with 
high, approximately 45%, risk of treatment-related mortality 
(TRM) [9]. Consequently, a concept of reduced-intensity 
conditioning (RIC) was developed, in order to decrease 
the treatment toxicity and TRM without compromising the 
GVM effect. Then, the idea of RIC allogeneic transplantation 
(also referred to as “mini allo”) following the autologous 
transplant was introduced by the Seattle group. However, 
despite a plethora of comparative studies of tandem auto 
and autologous/RIC allogeneic transplantations that have 
been conducted since then, there are still more questions 
than answers. Who? When? According to which protocol? 
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The role of alloSCT in MM is still a matter of debate due to 
high treatment-related mortality and morbidity and the 
lack of convincing evidence for a survival benefit. No tre-
atment strategy should be implemented to routine clinical 
practice if there are still too many questions that have not 
been adequately addressed by researchers. Consequently, 
in this paper we try to answer the question “Why not to use 
alloSCT in MM patients?”.
High risk plus high risk make ultra-high risk
According to the data from the Institute of Hematology 
and Transfusion Medicine in Warsaw, a total of 60 allogeneic 
stem cell transplantations were performed in Polish MM 
patients in 1993–2016. This included 26% of patients who 
underwent myeloablative conditioning and 74% subjected 
to reduced intensity conditioning. The median age of the 
patients was 46 years. Overall survival (OS) and PFS amoun-
ted to 26 and 23 months respectively. Thirty-seven patients 
(62%) died. The primary causes of TRM were disease progres-
sion, infections and graft-versus-host disease (GVHD) (Fig. 1).
According to the European Bone Marrow Transplan-
tation (EBMT) report, TRM associated with myeloablative 
conditioning may reach up to 45%, with infections, GVHD 
and regimen-related toxicities as primary mortality causes 
[10, 11]. When the outcomes of 334 patients who received 
myeloablative alloSCT in 1983–1993 were compared with 
the results of 356 patients treated with the same methods 
in 1994–1998, a decrease in 2-year TRM rate was documen-
ted, from 46% to 30% [12]. Nevertheless, the TRM rate was 
still unacceptably high. As a result, at the end of the 20th 
century, myeloablative alloSCT was no longer performed 
in most countries [13]. Some authors compared the outco-
mes of ASCT and myeloablative alloSCT [14, 15]. Although 
myeloablative alloSCT resulted in sustained responses in 
some patient subpopulations and, therefore, seemed to 
have a curative potential in MM [16], the treatment was 
associated with high TRM (> 30%), even when applied as 
a component of the first-line therapy [15]. Based on those 
findings, myeloablative alloSCT definitely should not be 
considered a treatment of choice, especially when taking 
into account that long OS can also be achieved through 
effective induction therapy and ASCT.
The promising outcomes of RIC alloSCT in patients with 
low-grade lymphoproliferative disorders again stimulated 
a discussion about the role of allotransplantation as a treat-
ment option in MM. The researchers from the Seattle group 
conducted a pioneering study of autologous transplantation 
followed by RIC allografting. The treatment consisted of high-
-dose melphalan and autograft, followed by 2 Gy total body 
irradiation (TBI), with fludarabine or without it, and alloSCT 
from HLA-identical siblings. The five-year non-relapse morta-
lity rate after the allografting was 18%; up to 95% of the fatal 
outcomes resulted from GVHD or infection [17]. A number of 
conditioning regiments (including various doses of melphalan, 
fludarabine, cyclophosphamide and busulfan, with TBI or wi-
thout it) and various anti-GVHD preventive measures, among 
them anti-thymocyte globulin (ATG) and alemtuzumab, were 
tested in further studies [18–26]. TRM rates varied between 
11% and 38%. However, those results should be interpreted 
with caution, considering heterogeneity of patient populations 
and study protocols, and no definite conclusions should be 
drawn with regards to the superiority of any treatment regi-
men in terms of its efficacy and safety. In recent large studies 
[27–29], TRM rates at one year after alloSCT were 21–23% and 
then increased to 38% at two years from the transplantation 
(Tab. I). The only significant determinant of greater TRM was 
the age above 50 years [27]. This is quite an important finding, 
considering that MM is a disease of the elderly, with a median 
age at the diagnosis amounting to 70 years [2].
The authors of the EBMT report compared the outcomes 
of RIC alloSCT (in 320 patients) and myeloablative alloSCT (in 
196 patients) [30]. While TRM at two years was significantly 
lower after RIC alloSCT (24% vs 37%, p = 0.002), the two 
groups did not differ in terms of OS, and higher PFS rate was 
documented in the myeloablative alloSCT group (34.5% vs 
18.9%, p = 0.001). Multivariate analysis demonstrated that 
RIC alloSCT was associated with lower likelihood of TRM 
(HR = 0.5), but higher relapse risk (HR = 2.0). Based on those 
findings, it cannot be concluded what the optimal type 
and intensity of the induction are; while deep, sustained 
treatment response is with no doubt a priority, it must not 
be achieved at the expense of the compromised safety of 
the patient and greater toxicity of the therapy.
GVHD is one of the most significant contributors to 
TRM. Classic acute GVHD (aGVHD) is diagnosed whenever 
the disease manifestations (erythema, maculopapular rash, 
nausea, vomiting, anorexia, profuse diarrhea, ileus, or cho-
lestatic liver disease) occur within the first 100 days after 
Figure 1. Causes of treatment-related mortality in 37 Polish 
patients with multiple myeloma subjected to allogeneic stem cell 
transplantation in 1993–2016. Data courtesy of the Institute of 
Hematology and Transfusion Medicine in Warsaw. MM — multiple 
myeloma, GVHD — graft-versus-host disease
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the transplantation, and classic chronic GVHD (cGVHD) is 
defined as the disease without any characteristic features 
of aGVHD [31]. In the previously mentioned pioneering 
study of autologous transplantation followed by RIC allo-
grafting, conducted by the researchers from Seattle, grade 
II–IV aGVHD was documented in 42% of the recipients at 
a median of 42 days post-transplantation (range 8–107), and 
cGVHD was diagnosed in 74% of the patients at a median 
of 167 days after the allografting (range 90–830) [17]. As 
shown in Table II, the risk of GVHD after alloSCT is unac-
ceptably high. Even if only high-risk allograft recipients are 
considered, the likelihood of aGVHD exceeds 50% [27–29]. 
In one study, the incidence of grade II–IV aGVHD was shown 
to be significantly lower in patients subjected to RIC alloSCT 
than in those after myeloablative alloSCT (35.5% vs 45.9%, 
p = 0.02); the risk of aGVHD and its severity were not asso-
ciated with the implementation of GVHD prophylaxis, use 
of a T-cell depletion, source of stem cells, and any specific 
donor-recipient sex combinations [30]. Moreover, no link 
was found between the type of conditioning regimen and 
the development of cGVHD or the severity thereof. The use 
of a T-cell depletion was associated with a lesser incidence of 
cGVHD (53.7% vs 77%, p < 0.001), but higher risk of disease 
relapse or progression (HR = 2.0, 95% CI 1.4–2.9, p < 0.001), 
plausibly due to an attenuation of the GVM effect. Higher 
incidence of cGVHD was also observed in male recipient-
-female donor combinations (60% vs 46%, p < 0.001) and 
in patients who received peripheral blood stem cells (51.5% 
vs 44.7%, p = 0.03) [30]. GVHD is a key determinant of su-
rvival and a principal factor limiting the use of alloSCT in 
MM. aGVHD was shown to be associated with higher TRM 
rates (32.5% in patients with grade II–IV aGVHD vs 14.8% in 
recipients with grade 0–I aGVHD, p < 0.001) and lower OS 
rates at three years (43% vs 56%, p < 0.001) [30].
To summarize, available evidence shows that alloSCT 
results in profound GVM effect, which may contribute to 
long-term remission. However, owing to high TRM rates 
after alloSCT, even used as a frontline therapy, this treatment 
should always be considered inferior to ASCT. The principal 
limitations for routine use of alloSCT in MM patients seem to 
be high mortality and high risk of potential complications. 
Moreover, allotransplantation is known to additionally in-
crease the already high cytogenetic risk to an ultra-high, 
unacceptable level. Considering all the above, the Latin sen-
tence Primum non nocere becomes particularly meaningful.
Is it worth it?
A final therapeutic decision should be based on a careful 
analysis of the risk-to-benefit ratio. The efficacy of alloSCT 
can be verified by prospective comparison of auto/allotran-
splantation with a gold standard, tandem autotransplanta-
tion. However, biologic randomization for alloSCT based on 
the availability of an HLA-identical sibling donor is a widely 
accepted and reliable surrogate criterion. Unfortunately, 
the studies using this protocol showed unequivocally that 
alloSCT is no more effective than ASCT.
The most definite conclusions about the role of alloSCT 
in standard-risk MM originate from a very large (710 patients 
Table I. Treatment-related mortality in multiple myeloma patients subjected to allogeneic stem cell transplantation
Study N Median age Stage Cytogenetics RIC Follow-up TRM
Schilling et al. 
[27]
101 52 years ISS III (74%) FISH(+): 71% yes 1 year 21%
Kröger et al. 
[28]
73 49 years ISS II/III del(13q): 59%
t(4;14): 11%
del(17p): 11%
yes 1 year 23%
Roos-Weil et al.  
[29]
143 51 years D&S III (81%) del(13q): 59%
t(4;14): 25%
del(17p): 25%
t(14;16): 4%
yes 
(77%)
2 years 20%
29%
38%
23%
RIC — reduced intensity conditioning, TRM — treatment-related mortality, ISS — International Staging System, D&S —Durie and Salmon stage, FISH — fluorescence in situ 
hybridization
Table II. The incidence of acute and chronic graft-versus-host disease in multiple myeloma patients subjected to allogeneic stem cell transplantation
GVHD Schilling et al. [27] (n = 101) Kröger et al. [28] (n = 73) Roos-Weil et al. [29] (n = 143)
Acute overall: 39%
grade I: 13%
grade II: 21%
grade III: 1%
grade IV: 4%
overall: 57%
grade I: 17%
grade II: 27%
grade III: 12%
grade IV: 1%
overall: 47%
grade II–IV: 32%
Chronic 24% 26% (in patients who achieved CR) 43% (100 days post-transplantation)
GVHD — graft-versus-host disease, CR — complete response
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from 37 transplant centers) Blood and Marrow Transplant 
Clinical Trials Network (BMT CTN) phase III tandem auto vs 
auto/mini allo trial. The study did not demonstrate statisti-
cally significant differences between both regimens in terms 
of PFS and OS rates at three years [32]. Noticeably, patients 
from the auto/mini allo arm more often suffered from com-
plications related to organ dysfunction and immune system 
deregulation resulting from chronic immunosuppression 
and the development of GVHD or the treatment thereof. 
Also, TRM rate in the auto/mini allo arm turned out to be 
significantly higher than in the tandem auto group (11% vs 
4%, p < 0.001), even despite the use of a non-myeloablative 
regimen; the primary causes of mortality were GVHD and 
infections. Thus, a potential beneficial effect of GVM was 
outweighed by the increase in TRM.
Before the era of novel agents, prognosis in patients with 
unfavorable cytogenetics, i.e. with t(4,14), t(14,16) and/or 
del(17p) was generally poor [33, 34]. Thus, the discovery of 
donor-mediated GVM raised many hopes as a potentially 
effective treatment in high-risk MM. The French Intergroupe 
Francophone du Myelome (IFM) conducted two parallel 
phase II trials in patients with high-risk MM (beta-2-micro-
globulin > 3 mg/l and the presence of 13q deletion con-
firmed by fluorescent in situ hybridization). The IFM99-03 
study included 65 patients with available HLA-matched 
sibling donors, who received RIC alloSCT after ASCT with 
busulfan, fludarabine and ATG conditioning. The outcomes 
of this group were compared with the results of 219 partici-
pants of IFM99-04, the auto-auto dose-intensified (220 mg/
m2), melphalan-based trial. No significant between-group 
differences in event-free survival (EFS) and OS rates were 
found in the intent-to-treat analysis [35]. While the two 
arms did not differ significantly in terms of their TRM rates, 
the incidence of relapse/progression was markedly higher 
in the RIC alloSCT group (56.5%); this might be associated 
with the fact that the outcomes were analyzed solely in high-
-risk patients and the GVM effect might have been partially 
attenuated due to the use of conditioning regimen prior to 
the allotransplantation [30, 36]. In updated IFM study [37], 
patients subjected to tandem ASCT and individuals who 
received ASCT/RIC alloSCT were followed-up for a median 
of 56 months. While the study groups did not differ signifi-
cantly in terms of median EFS (22 vs 19 months, p = 0.58), 
median OS tended to be better in patients from the tandem 
ASCT arm (48 vs 34 months, p = 0.07). However, it must be 
stressed that the study was criticized for the use of high-dose 
ATG conditioning (12.5 mg/kg), as it might have a negative 
impact on GVM and contribute to a relatively low proportion 
of complete responses (CR, 23%) [36].
Schilling et al. [27] conducted a retrospective analysis of 
101 patients subjected to RIC alloSCT. While participants of 
this study presented with an array of various cytogenetic ab-
normalities, including del(13q14) (61%), t(4;14)(p16.3;q32) 
(19%), del(17p13) (16%) and t(14;16)(q32;q23) (5%), cyto-
genetic profile exerted no effect on treatment responses 
and TRM rates. In a prospective study of 100 patients with 
newly diagnosed MM, all younger than 65 years, Bruno 
et al. [18] found no significant differences in median OS 
of individuals with del(13)q and without (4.3 years vs not 
reached, p = 0.18); nevertheless, patients without del(13) 
had better median EFS than those presenting with this cy-
togenetic defect (4.3 vs 2.2 years, p = 0.01). Unfortunately, 
due to a small number of patients included in the studies 
mentioned above, we still cannot conclude whether RIC 
alloSCT may provide an additional benefit in patients with 
unfavorable cytogenetics.
Whether the patient was subjected to tandem ASCT 
or auto/allotransplantation, relapse of MM seems to be 
a major problem. This puts particular emphasis on long-
-term control of the disease and identification of patients in 
whom MM is more likely to relapse. A multivariate analysis 
conducted within the framework of a large retrospective 
study [29] demonstrated that better PFS at three years was 
associated with younger age at the transplantation and at 
least very good partial response (VGPR) to alloSCT, whereas 
larger number of prior therapies and presence of cGVHD 
were identified as independent predictors of worse survival 
(Tab. III). These findings point to effective frontline therapy 
with ASCT as a key determinant of sustained response to 
the first-line treatment.
According to Keith Stewart from the Mayo Clinic: “The 
continued pursuit of safe and effective allogeneic stem cell 
transplantation for myeloma appears to be a triumph of 
hope over experience” [38]. However, the results of three 
randomized trials [17, 18, 39] suggest that the long-term out-
comes of RIC alloSCT in MM are not encouraging; 11–18% 
of patients died within five years of the allotransplantation 
(most of them within the first two years), 50–74% developed 
a severe cGVHD, and one-third still required immunosup-
pressive therapy at five years post-alloSCT. Furthermore, 
no statistically significant differences were found in PFS 
and OS of patients subjected to alloSCT and tandem ASCT. 
Finally, little is known about a survival plateau after the 
allotransplantation. AlloSCT was shown to be inferior to 
Table III. Independent predictors of better progression-free survival 
in multiple myeloma patients with high cytogenetic risk subjected to 
allogeneic stem cell transplantation
Predictor HR (95% CI) p-value
Number of treatment lines 0.29 (0.15–0.56) 0.0002
Age at the transplantation 1.1 (1.01–1.18) 0.01
At least VGPR after alloSCT 2.0 (1.11–3.62) 0.02
Chronic GVHD 0.3 (0.16–0.52) 0.001
Based on Roos-Weil et al. [29]. PFS — progression-free survival, VGPR — very 
good partial response, alloSCT — allogeneic stem cell transplantation, GVHD —
graft-versus-host disease, HR — hazard ratio, CI — confidence interval
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tandem ASCT even in patients at very high risk of early 
progression and death from the disease. Paradoxically, the 
only group that may benefit from RIC alloSCT, are not the 
high-risk patients, but individuals with a favorable prognosis 
and expected survival of up to 10 years [38]. This seems 
to be the additional argument against the routine use of 
allotransplantation in MM patients.
The potential of youth, the power of medicines
Over the last two decades, the survival of younger MM 
patients had improved significantly due to the use of novel 
anti-MM agents. In 1996 Blade et al. evaluated the outco-
mes of 72 MM patients younger than 40 years [40]. Median 
overall survival in patients treated with a single alkylating 
agent or combined chemotherapy was 54 months, while 
the actuarial survival at 5 and 10 years after initiation of the 
therapy amounted to 43% and 13% respectively. Implemen-
tation of novel therapies resulted in a marked improvement 
of the treatment outcomes. In our recent study, including 
173 patients between 21 and 40 years of age treated with 
proteasome inhibitors and immunomodulatory agents 
and undergoing ASCT [41], median overall survival was 
not reached, and 5- and 10-year OS rates were 83% and 56% 
respectively. After stratification for the ISS stage, younger 
MM patients still had a better OS than those aged 41–60 
years, but the survival advantage was observed solely for 
lower ISS stages.
Nowadays, a standard of care in patients who had been 
diagnosed with MM ≤ 65 years of age is high-dose mel-
phalan followed by ASCT (HDT-ASCT); median OS after the 
treatment approximates 4 to 6 years [42–44]. In patients who 
failed to achieve at least near complete response (nCR) [42], 
or even VGPR [44], after the first transplantation tandem 
ASCT may produce additional benefits. Hence, the primary 
objective in treatment-naïve MM patients is to achieve CR 
or at least VGPR to induction therapy [45]. In the past, vin-
cristine plus doxorubicin plus dexamethasone (VAD) was 
a  standard induction therapy prior to HDT-ASCT [14, 35, 
42, 44] with CR rates below 10% [14, 46, 47]. Novel agents, 
i.e. proteasome inhibitors (such as bortezomib) and immu-
nomodulatory drugs (e.g. thalidomide or lenalidomide) are 
more effective, both in patients with newly diagnosed MM 
and in those with the disease relapse [48, 49]. In an open-
-label phase III study comparing the efficacy and safety of 
bortezomib plus dexamethasone (Vd) and VAD as induction 
treatments prior to ASCT in 482 previously untreated MM 
patients, significantly higher post-induction CR/nCR (14.8% 
vs 6.4%), at least VGPR (37.7% vs 15.1%) and overall response 
(ORR) rates (78.5% vs 62.8%) were documented the Vd arm 
[50]. Vd induction turned out to be superior to VAD even 
in patients with t(4,14), as shown by statistically significant 
differences in EFS (28 vs 16 months, p < 0.001) and OS rates 
at four years (63% vs 32%, p < 0.001) [51]. All these findings 
suggest that it is the induction therapy regimen rather than 
the type of the graft, which has a stronger impact on survival, 
also in high-risk patients [51].
Until recently, however, the use of the novel agents 
has been limited to patients with particularly unfavorable 
prognosis, with high-risk relapsed and refractory MM. Ja-
kubowiak et al. [52] prospectively analyzed the impact of 
cytogenetic abnormalities, such as del(17p), t(4;14), t(14;16), 
del(13) and hypodiploidy, on the outcomes of carfilzomib 
therapy during a phase II trial. Although they found no 
statistically significant difference in ORR between the high-
-risk and non-high-risk group (25.8% vs 24.6%, p = 0.85), 
patients from the former group had significantly shorter 
OS (9.3 vs 19 months, p = 0.0003). In the study conducted 
by Shah et al. [53], patients with relapsed and refractory 
MM and poor cytogenetics, including del(17p), responded 
well to combination therapy with carfilzomib, pomalido-
mide and dexamethasone (CPD), which resulted in susta-
ined control of the disease. The efficacy of novel agents in 
del(17p) carriers was also confirmed in a multicenter phase 
II randomized trial using the combination of pomalidomide 
and dexamethasone in advanced MM [54].
Some yet unpublished evidence suggests that also novel 
immunotherapies, such as bispecific antibodies and chime-
ric antigen receptor (CAR) T cells may provide a treatment 
benefit in ultra-high risk MM patients. However, those treat-
ments are associated with up to 5% TRM, and hence, before 
their implementation in clinical practice, more data need to 
be collected about their long-term efficacy, especially PFS.
Due to the lack of treatment algorithms for this group, 
therapy of high-risk MM patients needs to be personalized, 
and pharmacotherapy offers much more possibilities in 
this matter than transplantation. Younger patients are by 
default more immunocompetent, and further boosting of 
their immune responses with novel agents seems to be 
a better option than exposure to toxicity associated with 
allografting.
Conclusions
A considerable improvement in the outcomes of MM 
treatment observed in the last decade is primarily rela-
ted to the implementation of novel agents. Nowadays, 
the vast majority of younger patients receiving novel the-
rapies may achieve sustained, prolonged remissions, and 
exposing them to morbidity and mortality risks related to 
alloSCT does not seem to be justified, even considering a 
potential additional survival benefit. Although a small pro-
portion of patients may benefit from myeloablative allo-
SCT, this treatment is associated with high TRM rates, even 
when implemented as frontline therapy. While TRM after RIC 
alloSCT tends to be lower, this treatment is also associated 
with higher risk of relapse or progression. Further, we still do 
not have enough evidence for the superiority of alloSCT over 
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ASCT [55], and even if it was the case, the applicability of al-
lotransplantation as the first line treatment still might raise 
controversies considering already proven efficacy of novel 
agents, such as proteasome inhibitors and immunomodulators. 
AlloSCT still may be an option in patients with high-risk 
MM and poor long-term prognosis. In this group, allotran-
splantation may be considered as a frontline therapy or as 
a salvage treatment after the failure of the first-line chemo-
therapy, but only when the risk of the disease progression 
outweighs the transplant-related threats.
The International Myeloma Working Group clearly sta-
ted that RIC alloSCT should only be recommended in the 
context of clinical trials. Future studies of allotransplantation 
in MM should be aimed at strengthening of the GVM effect 
with a simultaneous decrease in morbidity and mortality 
associated with GVHD [13]. This recommendation stays in 
agreement with the National Comprehensive Cancer Ne-
twork guidelines on the treatment of myeloma.
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